Teachers Advisors’s Protara Therapeutics TARA Stock Holding History

Teachers Advisors’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-282	Closed	-$87K	–	3152
2016 Q1	$87K	Hold	282	–	–	﹤0.01%	2963
2015 Q4	$175K	Hold	282	–	–	﹤0.01%	2907
2015 Q3	$157K	Hold	282	–	–	﹤0.01%	2945
2015 Q2	$202K	Buy	+282	New	+$174K	﹤0.01%	2966

Other funds holding TARA

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

DVC

Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Teachers Advisors's TARA Position: Q2 2016 in Review

Teachers Advisors sold out of Protara Therapeutics (TARA) in Q2 2016, closing a stake of 282 shares — an estimated $87K sold.

Teachers Advisors first reported a position in TARA in Q2 2015 and held it in 4 quarters. The position peaked at $202K in Q2 2015. 32 funds tracked by Wall St. Rank hold TARA as of Q2 2016.

Teachers Advisors reported no remaining Protara Therapeutics position as of Q2 2016 after selling out during the quarter.
Teachers Advisors sold 282 Protara Therapeutics shares in Q2 2016, an estimated $87K.
Teachers Advisors first reported a position in Protara Therapeutics in Q2 2015 and held it in 4 quarters.
Teachers Advisors's Protara Therapeutics position peaked at $202K in Q2 2015.
32 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2016.

Based on Teachers Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.